CYP2D6 phenotype and the metabolism of nicotine and cotinine

被引:23
作者
Benowitz, NL
Jacob, P
PerezStable, E
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA
[2] UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
nicotine; cotinine; metabolism; CYP2D6;
D O I
10.1097/00008571-199606000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
That CYP2D6 activity is an important determinant of nicotine metabolism and that people who have abnormal CYP2D6 genes are poor metabolizers of nicotine has been reported in the medical literature. The aim of this study was to assess the role of CYP2D6 in nicotine metabolism, Specifically, we compared the clearance of stable isotope-labelled nicotine and cotinine in 11 poor and 33 extensive metabolizers of dextromethorphan, a probe for CYP2D6 activity, The groups were matched by gender, age and ethnicity, Nicotine and cotinine kinetics were quite similar for cases and controls, These data suggest that CYP2D6 is nob a major isozyme for the metabolism of nicotine or cotinine.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 15 条
  • [11] SELECTED ION MONITORING METHOD FOR DETERMINATION OF NICOTINE, COTININE AND DEUTERIUM-LABELED ANALOGS - ABSENCE OF AN ISOTOPE EFFECT IN THE CLEARANCE OF (S)-NICOTINE-3',3'-D2 IN HUMANS
    JACOB, P
    YU, L
    WILSON, M
    BENOWITZ, NL
    [J]. BIOLOGICAL MASS SPECTROMETRY, 1991, 20 (05) : 247 - 252
  • [12] McCracken N. W., 1992, Medical Science Research, V20, P877
  • [13] LOWER PREVALENCE OF THE DEBRISOQUIN OXIDATIVE POOR METABOLIZER PHENOTYPE IN AMERICAN BLACK VERSUS WHITE SUBJECTS
    RELLING, MV
    CHERRIE, J
    SCHELL, MJ
    PETROS, WP
    MEYER, WH
    EVANS, WE
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) : 308 - 313
  • [14] POLYMORPHIC DEXTROMETHORPHAN METABOLISM - CO-SEGREGATION OF OXIDATIVE O-DEMETHYLATION WITH DEBRISOQUIN HYDROXYLATION
    SCHMID, B
    BIRCHER, J
    PREISIG, R
    KUPFER, A
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (06) : 618 - 624
  • [15] TURGEON J, 1995, CLIN PHARMACOL THER, V57, P150